Hyaluronidase Power Injection Market Analysis

Source (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase, Bio-Engineered Hyaluronidase)

The animal-derived hyaluronidase segment in the hyaluronidase power injection market is projected to hold its position with over 55% of revenue share by the end of the predicted timeline. It is because most licensed and advertised brands, at present, are taken from animal sources, and the most commonly implemented animal sources are bovine and porcine products. To illustrate, the US FDA has approved the recombinant human hyaluronidase PH20 (rHuPH20) which works locally to provisionally eliminate the glycosaminoglycan hyaluronan’s barrier, enabling quick subcutaneous (SC) submission of large volumes and/or high doses of successively or co-directed therapeutics. Moreover, the animal-derived hyaluronidase market has witnessed a substantial number of product approvals, contributing to the massive demand for the animal-derived hyaluronidase segment in the coming years.

Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology)

Hyaluronidase power injection market from the dermatology segment held the largest profit share in 2023 and is estimated to hold this position with approximately 45% revenue share by the end of 2037. The increasing importance of hyaluronidase power injections’ safety in dermatology has resulted in the highest profit production. In December 2021, a research study released by the American Society for Dermatologic Surgery (ASDA) expressed that hyaluronic acid fillers VYC-20I were harmless and efficient for cheek augmentation via cannula and noninferior to needle injection.  Utilizing cannulas to provide facial fillers may limit negative events (AEs) in comparison with needle injection. The setup of a standard technique is anticipated to modify the momentum of market expansion in the future.

Our in-depth analysis of the global hyaluronidase power injection market includes the following segments: